Explanipedia

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis Open

Jai Perumal, Roumen Balabanov, Laura J. Balcer, Steven Galetta, Zhaonan Sun , et al. · 2023

Epsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege Open

Yinghua Ma, David R. Sannino, Jennifer R. Linden, Sylvia Haigh, Baohua Zhao , et al. · 2023

Multiple sclerosis (MS) is a complex disease of the CNS thought to require an environmental trigger. Gut dysbiosis is common in MS, but specific causative species are unknown. To address this knowledge gap, we used sensitive and quantitati…

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study Open

Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J. Balcer , et al. · 2023

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study Open

Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J. Balcer , et al. · 2022

Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis Open

Melanie Marcille, Sandra Hurtado Rúa, Charles Tyshkov, Abhishek Jaywant, Joseph P. Comunale , et al. · 2022

Disease Correlates of Rim Lesions on Quantitative Susceptibility Mapping in Multiple Sclerosis Open

Melanie Marcille, Sandra Hurtado Rúa, Charles Tyshkov, Abhishek Jaywant, Joseph P. Comunale , et al. · 2021

Quantitative susceptibility mapping (QSM), an imaging technique sensitive to brain iron, has been used to detect paramagnetic rims of iron-laden active microglia and macrophages in a subset of multiple sclerosis (MS) lesions, known as rim+…

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study Open

Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J. Balcer , et al. · 2021

A correction to this paper has been published: https://doi.org/10.1007/s12325-021-01815-6

Disease correlates of quantitative susceptibility mapping rim lesions in multiple sclerosis Open

Melanie Marcille, Sandra Hurtado Rúa, Charles Tyshkov, Abhishek Jaywant, Joseph P. Comunale , et al. · 2021

Objective This study aimed to explore the association between chronic active rim+ lesions, identified as having a hyperintense rim on quantitative susceptibility mapping (QSM), on both clinical disability and imaging measures of neurodegen…

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study Open

Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J. Balcer , et al. · 2021

Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions Open

Sneha Pandya, Ulrike W. Kaunzner, Sandra Hurtado Rúa, Nancy Nealon, Jai Perumal , et al. · 2020

BACKGROUND AND PURPOSE To examine the impact of lesion location on longitudinal myelin water fraction (MWF) changes in chronic multiple sclerosis (MS) lesions. Relative hypoxia, due to vascular watershed regions of the cerebrum, has been i…

A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis Open

Yeona Kang, Sandra Hurtado Rúa, Ulrike W. Kaunzner, Jai Perumal, Nancy Nealon , et al. · 2020

Black African and Latino/a identity correlates with increased plasmablasts in MS Open

Kiel M. Telesford, Ulrike W. Kaunzner, Jai Perumal, Susan A. Gauthier, Xian Wu , et al. · 2019

The enhanced peripheral blood plasmablast signature revealed among Black African or Latin American subjects with MS points to distinct underlying mechanisms associated with MS immunopathogenesis. This dysregulation may contribute to the di…

Multiplex PCR based detection of mecA, mecC and PVL gene in analysis of prevalence, circulation, transmission of MSSA/MRSA strains in a tertiary care hospital Open

Srinivas Jayanthi, S H. Shifa Meharaj, D. Danisvijay, A. Sujhithra, Jai Perumal · 2019

Introduction: Staphylococcus aureus a Gram positive cocci causes major and minor infections in humans. It is the most important pathogen causing Hospital acquired and community-acquired (CA) infections. The commonest being the Methicillin …

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE Open

Jai Perumal, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta , et al. · 2019

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis Open

Robert J. Fox, Christopher S. Coffey, Robin Conwit, Merit Cudkowicz, Trevis Gleason , et al. · 2018

In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and …

Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation Open

Ulrike W. Kaunzner, Yeona Kang, Elizabeth Monohan, Paresh J. Kothari, Nancy Nealon , et al. · 2017

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis Open

Robert J. Fox, Christopher S. Coffey, Merit Cudkowicz, Trevis Gleason, Andrew Goodman , et al. · 2016

A study of patients with aggressive multiple sclerosis at disease onset Open

Ulrike W. Kaunzner, Gaurav Kumar, Gülce Askin, Susan A. Gauthier, Nancy Nealon , et al. · 2016

With recognition of the crucial significance of early optimal treatment during the potential window of opportunity for best long-term outcomes, we describe AOMS within 1 year of disease onset and discuss possible treatment considerations f…

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis Open

Jai Perumal, Rachel Babij · 2015

Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B lymphocytes, monocytes, natural killer cells, macrop…

Disease exacerbation after rituximab induction in neuromyelitis optica Open

Jai Perumal, Ilya Kister, Jonathan Howard, Joseph Herbert · 2015

Rituximab (RTX), an anti-CD20 monoclonal antibody, was highly efficacious in reducing relapse rates in neuromyelitis optica (NMO) in several observational case series.1–7,e1-e3 Despite the favorable record, most series include 1 or more pa…

Jai Perumal YOU? Author Swipe